Overview

Corporate Profile

CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer.

CytRx's initial focus is on seeking regulatory approval for and commercialization of our lead drug candidate, aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin.. ... More >>

Upcoming Events

Oct 17, 2017 at 10:00 AM PDT

Special Meeting of Shareholders

Location: Loeb & Loeb LLP, 10100 Santa Monica Blvd., 18th FL, Los Angeles, CA 90067

 NASDAQ Financial Status Indicator
Value Description
D Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
E Delinquent: Issuer Missed Regulatory Filing Deadline
Q Bankrupt: Issuer Has Filed for Bankruptcy
N Issue is not currently deficient, delinquent, or bankrupt.
G Deficient and Bankrupt
H Deficient and Delinquent
J Delinquent and Bankrupt
K Deficient, Delinquent, and Bankrupt

Stock Chart

Stock Quote

Featured Report

Contact Information

David Haen
CytRx Corporation
Vice President, Business Development and Investor Relations
(310) 826-6498
dhaen@cytrx.com